

Lantheus Medical Imaging to Present at Imperial Capital Global Opportunities Conference on September 19, 2013

September 10, 2013 1:50 PM ET

FOR IMMEDIATE RELEASE

CONTACTS:

Lantheus Medical Imaging

Linda Lennox
978-671-8854

Pure Communications

Michele Rozen
617-730-8284

Meara Murphy
978-671-8508

**Lantheus Medical Imaging to Present at Imperial Capital
Global Opportunities Conference on September 19, 2013**

N. Billerica, Mass., September 10, 2013 – [Lantheus Medical Imaging, Inc.](http://www.lantheus.com), a global leader in developing, manufacturing and distributing innovative diagnostic imaging agents, today announced that Jeff Bailey, President and Chief Executive Officer, will present at the Imperial Capital Global Opportunities Conference in New York City. The presentation will take place on Thursday, September 19, 2013, at 9:30 a.m., Eastern Time. Mr. Bailey will provide an overview of the Company and business update.

To access a live webcast of the presentation, please visit the Company's website at www.lantheus.com. A replay of the presentation will be available on the Company's website for 30 days following the live presentation.

About Lantheus Medical Imaging, Inc.

Lantheus Medical Imaging, Inc., a global leader in developing, manufacturing and distributing innovative diagnostic imaging agents, is dedicated to creating and providing pioneering medical imaging solutions to improve the treatment of human disease. The Company's proven success in the field of diagnostic imaging provides a strong platform from which to bring forward breakthrough tools for the diagnosis and management of disease. Lantheus imaging products include the echocardiography contrast agent DEFINITY[®] Vial for (Perflutren Lipid Microsphere) Injectable Suspension, an ultrasound contrast agent for use in patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border, TechnoLite[®] (Technetium Tc99m Generator), Cardiolite[®] (Kit for the Preparation of Technetium Tc99m Sestamibi for Injection), and Thallium 201 (Thallous Chloride Tl 201 Injection). Lantheus has approximately 550 employees worldwide with headquarters in North Billerica, Massachusetts, and offices in Puerto Rico, Canada and Australia. For more information, visit www.lantheus.com.

###